GW Pharmaceuticals (NASDAQ:GWPH) has filed a
supplemental marketing application in Europe seeking approval to use
Epidiolex (cannabidiol) to treat seizures associated with Tuberous Sclerosis Complex, a rare inherited disorder characterized by non-cancerous tumors in the brain (causing seizures) and other organs.
It filed a similar application in the U.S. in early February.
The European Commission approved Epidiolex in
September 2019 for the treatment of seizures associated with Dravet and
Lennox-Gastaut syndromes.
Shares up 4% premarket on light volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.